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tablished multiples abscesses in cerebrum, cerebellum, choroid,
vitreous humor, spinal cord, and meninges, where two (8.1%) of
25 CSF cultures were positive and 25 (100%) of simultaneous CSF
samples for (1→3)-β-D-glucan were positive with a range of 755
to 7750 pg/mL (p<0.001). Levels of (1,3)-β-D-glucan in CSF were
significantly greater than those of simultaneously obtained serum
samples in treated animals (n=94) and UC (p<0.05), suggesting
CNS compartmentalization of this polymeric biomarker. Clearance
of C. albicans from blood cultures was not predictive of eradica-
tion of organisms from CNS; whereas, reduction of CSF (1→3)-β-D-
glucan levels was predictive of therapeutic response. A significant
decrease of (1→3)-β-D-glucan concentration of CSF started at 0.5
mg/kg/day in comparison to that of UC (p<0.001). Fungemia per-
sisted in all untreated controls. Positive blood cultures converted
to negative with MICA and DAmB within one day after treatment,
while CNS tissues remained positive for C. albicans. By compar-
ison, CSF (1→3)-β-D-glucan levels correlated directly in a dose-
dependent pattern with therapeutic response and residual fungal
burden of C. albicans in cerebral tissue (r=0.842).
Conclusions: (1→3)-β-D-Glucan in CSF is a surrogate marker for
detection and therapeutic response of hematogenous candida
meningoencephalitis.
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Background: Zygomycetes are emerging fungal pathogens that
cause life-threatening pneumonia in cancer patients, especially
during prolonged neutropenia and corticosteroid therapy. Little
is known about the relation between different species of Zy-
gomycetes and their pathogenesis in pulmonary zygomycosis.
Objectives: To study the relative virulence of Rhizopus oryzae
(RO), Rhizopus microsporus (RM), Mucor circinelloides (MC), Mu-
cor indicus and Cunninghamella bertholletiae (CB) in experimental
pulmonary zygomycosis and the possible correlation with germina-
tion rate, metabolic activity, and circulating zygomycete-specific
DNA by qPCR.
Methods: Interspecies virulence was studied in experimental pri-
mary pulmonary zygomycosis in persistently neutropenic rabbits
by a panel of validated outcome variables. Sporangiospore germi-
nation kinetics were measured over 4 h. Hyphal metabolic activ-
ity was determined by XTT assays. Plasma levels of zygomycete-
specific DNA, as a surrogate biomarker for angioinvasion, were
measured by qPCR of two regions within the 28S rRNA gene.
Results: There were significant inoculum-dependent differences
in residual pulmonary fungal burden (CFU/g) among CB-, RM-,
and RO-infected rabbits (102-104 CFU/g, p<0.05), and significant
differences in organism-mediated pulmonary injury as measured
by lung weights in RM-, and RO-infected rabbits (p<0.05). CB
caused the highest lung weights, most extensive pulmonary
infarcts, and lowest survival of 0% (0/18), in comparison to 16%
(3/18, p<0.01) of RM-, 81% (21/26) of RO- and 83% (15/18) of M-
infections (p<0.001). Differences in virulence correlated with dif-
ferent germination kinetics at 4 h: CB (67-85%) > RM (14-56%) > RO
(4-30%) > MC and MI (0%). These data correlated with greater in
vitro metabolic activity by XTT assay of CB at 6 h (OD450=1.22)
in comparison to that of RM, RO, MC and MI (0.37-0.84). Mean
peak plasma zygomycete-specific DNA concentration (log GE/ml)
followed a similar pattern: CB > RM > RO > MC.
Conclusions: Medically important species of Zygomycetes differ
significantly in the outcome of pulmonary zygomycosis. Cunning-
hamella bertholletiae and Rhizopus microsporus were significantly
more virulent than Rhizopus oryzae and Mucor species. Viru-
lence parameters of zygomycosis in vivo correlate with species-
dependent differences in germination kinetics, hyphal metabolic
activity, and circulating levels of zygomycete-specific DNA.
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Background: Influenza vaccination is less immunogenic in trans-
plant recipients than healthy people. Influenza A (H1N1) and B
circulating viruses during the 2007-2008 epidemic were different
from those contained in this season' s vaccine.
Objective: To describe clinical and immunological characteristics
of 15 transplant recipients who developed influenza despite in-
fluenza vaccination (group A), and compare them to 6 transplant
recipients who developed influenza in the absence of influenza
vaccination (group B), 13 transplant recipients who did not develop
influenza (group C), and 8 healthy people who developed influenza
(group D.)
Methods: Case ascertainment through microbiology and electronic
medical records.
Results: Types of transplant: liver 3, heart 7, kidney 3, lung 8,
HSCT 8, kidney + pancreas 3, liver + kidney 1, liver + pancreas 1.
20 had influenza A, and 10 had influenza B (1 transplant recipi-
ent has both simultaneously.) Influenza occurred 1757 days (mean
[range 0-3850]) after transplant in group A, compared to 801 days
(range 20-3082) in group B. Influenza occurred 116 days (mean
[range 83-151] after vaccination in group A. There were no sta-
tistically significant differences in the incidence of fever, cough,
rhinorrhea, sore throat, malaise, shortness of breath, exposure to
contacts with similar symptoms, or presence of infiltrates on CXR
among groups A, B and D. Groups A and B were treated with os-
eltamivir significantly more frequently than Group D, [p=0.002].
Patients in group A were hospitalized more frequently than group
D [p=0.0002]. There were no statistically significant differences
in the incidence of pneumonia, ICU admission, mechanical ventila-
tion, or death among groups A, B and D. There were no statistically
significant differences between groups A, B and C in the incidence
of IgG < 600 mg/dL, immune function assay < 200 ng/mL, rejec-
tion (in SOT recipients) or GVHD (in HSCT recipients) in the pre-
ceding 30 days. Patients in group A were significantly more likely
to have concomitant infections than group D [p=0.049], but not
group B.
Conclusions: Influenza vaccination did not alter clinical presenta-
tion of influenza in transplant recipients, or impact the incidence
of complications. Transplant recipients who developed influenza
despite influenza vaccination were not more immunosuppressed
than those who were vaccinated and did not develop influenza,
and were more likely to have concomitant infections than healthy
people.
